In addition, Birnbaum et al. (2018) report a combination of sodium-dependent glucose transporters-2 inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitors can delay DKD progression, and that their therapeutic actions are closely related to the inhibition of NLRP3 inflammasome activation. This evidence concerns the gene DPP4 and diabetic kidney disease.